Suven Life Sciences Q2 Loss Widens to Rs 106.94 Crore on Higher R&D

Suven Life Sciences Limited reported a consolidated net loss of Rs 106.9421 crore for the quarter ended September 30, 2026, versus Rs 77.3099 crore a year earlier, as research and development expense rose to Rs 100.2999 crore from Rs 70.3213 crore. The loss was below the Rs 127.6103 crore reported in the June 2026 quarter.

What were Suven Life Sciences’ Q2 FY27 consolidated results?

Suven Life Sciences recorded total income of Rs 7.933 crore in the quarter ended September 30, 2026, compared with Rs 4.6972 crore in the year-earlier quarter and Rs 11.0894 crore in the June 2026 quarter. Its consolidated net loss was Rs 106.9421 crore, with no current-tax or deferred-tax expense reported in the quarterly statement.

Suven Life Sciences reported a total comprehensive loss of Rs 107.1765 crore for the September 2026 quarter, after other comprehensive loss of Rs 23.44 lakh. Basic and diluted loss per share was Rs 3.77, compared with Rs 3.48 in the September 2025 quarter; the company stated that quarterly per-share figures were not annualised.

Why did Suven Life Sciences’ consolidated loss widen year on year?

The year-on-year widening in Suven Life Sciences’ loss coincided primarily with a Rs 29.9786 crore increase in R&D expense, which rose to Rs 100.2999 crore in the September 2026 quarter from Rs 70.3213 crore a year earlier. Total expenses increased by Rs 32.868 crore to Rs 114.8751 crore, exceeding the Rs 3.2358 crore increase in total income.

Other reported cost lines also rose from the September 2025 quarter. Employee benefits expense increased to Rs 7.1896 crore from Rs 6.0765 crore, depreciation and amortisation rose to Rs 2.3023 crore from Rs 1.3168 crore, and other expenses reached Rs 4.6257 crore from Rs 4.2925 crore. Finance costs were Rs 45.76 lakh in the September 2026 quarter, whereas the comparable year-earlier figure was nil.

The sequential comparison moved differently because R&D expense declined by Rs 23.5311 crore from Rs 123.831 crore in the June 2026 quarter. Total expenses accordingly fell by Rs 23.8246 crore, while the loss narrowed by Rs 20.6682 crore; total income also declined by Rs 3.1564 crore over the same three-month comparison.

How did Suven Life Sciences’ income and expenses change in the first half?

Suven Life Sciences’ revenue from operations rose to Rs 1.1986 crore in the September 2026 quarter from Rs 91.92 lakh a year earlier, but fell from Rs 3.5658 crore in the preceding quarter. Other income remained the larger income component at Rs 6.7344 crore, compared with Rs 3.778 crore in the September 2025 quarter and Rs 7.5236 crore in June 2026.

For the six months ended September 30, 2026, Suven Life Sciences reported total income of Rs 19.0224 crore, up from Rs 7.1637 crore in the corresponding 2025 period. However, R&D expense rose to Rs 224.1309 crore from Rs 111.8097 crore and total expenses increased to Rs 253.5748 crore from Rs 135.9905 crore, resulting in a six-month net loss of Rs 234.5524 crore versus Rs 128.8268 crore.

Suven Life Sciences identified Research & Development as its only business segment and therefore did not present segment reporting under Indian Accounting Standard 108, which covers operating segments. The consolidated results include two wholly owned subsidiaries, Suven Neurosciences, Inc. and SuvenNeurosciences Pte. Ltd., the latter having been incorporated on July 14, 2026 and consolidated from that date.

What capital and subsidiary updates did Suven Life Sciences disclose?

Suven Life Sciences allotted 1,85,70,133 equity shares during the September 2026 quarter after conversion of the same number of fully paid warrants to 17 allottees. The company said it received 100% of the warrant consideration, amounting to Rs 248.8398 crore, for these conversions under its preferential issue.

As of September 30, 2026, Suven Life Sciences reported Rs 857.6402 crore raised through the preferential issue, Rs 537.6336 crore utilised and Rs 320.0066 crore unutilised. The board had approved issuance of 6,40,02,999 convertible warrants to 23 allottees on May 13, 2025, and shareholders approved the issue on June 5, 2025.

Paid-up consolidated equity share capital was Rs 28.2563 crore at September 30, 2026, compared with Rs 26.3993 crore at June 30, 2026 and Rs 22.7474 crore at September 30, 2025. Suven Life Sciences also granted 1,33,200 employee stock options on May 13, 2026 and recognised Rs 2.2096 crore of employee-benefit expense for the September quarter under its 2020 employee stock option scheme.

What did Suven Life Sciences report on its financial position?

Suven Life Sciences reported consolidated total assets of Rs 506.4223 crore at September 30, 2026, down from Rs 624.214 crore at March 31, 2026. Consolidated cash and cash equivalents increased to Rs 24.1278 crore from Rs 8.2791 crore, while bank balances other than cash equivalents declined to Rs 308.927 crore from Rs 329.177 crore.

Consolidated equity was Rs 453.5972 crore at September 30, 2026, compared with Rs 591.3997 crore at March 31, 2026, while total liabilities were Rs 52.8251 crore against Rs 32.8143 crore. Current other financial liabilities rose to Rs 27.888 crore from Rs 5.6399 crore over the same period.

The standalone cash-flow statement showed net cash used in operating activities of Rs 40.3896 crore for the half year ended September 30, 2026, compared with Rs 33.3975 crore in the corresponding 2025 period. Standalone investing cash outflow was Rs 53.3517 crore, including Rs 45.9143 crore for property, plant and equipment and Rs 198.5966 crore for changes in investments in subsidiaries, partly offset by Rs 169.6214 crore from sale or purchase of mutual funds.

Conclusion

Suven Life Sciences’ September-quarter result shows a larger year-on-year consolidated loss alongside a substantial increase in R&D expense and broader increases in employee, depreciation and other costs. The loss narrowed from the June 2026 quarter as R&D expense and total expenses declined, although revenue from operations and total income also fell sequentially.

The next disclosures to watch are the deployment of Rs 320.0066 crore of unutilised preferential-issue proceeds and any further conversion of the 6,40,02,999 warrants approved in May 2025. The company’s future results will also show whether R&D expense, which totalled Rs 224.1309 crore in the first half ended September 30, 2026, changes from its current pace.